ISRCTN34382898已完成不适用
Efficacy of subcutaneous interleukin-2 (IL-2) in the treament of advanced HIV-1 infections in persons with CD4+ T lymphoytes <100/mm3 and undetectable plasma viral load
Record provided by the NHS Trusts Clinical Trials Register - Department of Health (UK)0 个研究点目标入组 30 人开始时间: 2003年9月12日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Added June 2008:
- •1. Age equal to or greater than18 yrs old
- •2. HIV seropositive
- •3. On HAART (3 or more antiretroviral drugs)
- •4. HIV viral load < 400 copies/ml for = 3 months
- •5. CD4 count = 100 cells/mm3 despite points 3. & 4. above
排除标准
- •Added June 2008:
- •1. Active infection under investigation or treatment
- •2. Predicted poor compliance or poor attender
- •3. Pregnancy or breast-feeding
- •4. On-going treatment with interferon
- •5. Previous adverse reaction to IL-2
- •6. Clinically significant cardiac, pulmonary thyroid or neurologic impairment
- •7. Malignancy requiring systemic chemotherapy
- •8. Hb<9.5 g/dl, platelet count < 75,000/mm3, absolute neutrophil count < 1000 cells/mm3, serum creatinine> 2 times upper limit of normal (ULN), ALT >5 times ULN, bilirubin >2 times ULN (protease-induced hyperbilirubinaemia > 5 times ULN), amylase >2 times
研究者
相似试验
已完成
2 期
A Study to Evaluate the Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3HIV InfectionsNCT00000889National Institute of Allergy and Infectious Diseases (NIAID)72
进行中（未招募）
1 期
Safety and efficacy of low-dose interleukin-2 therapy in chronic inflammatory barrier diseases (IL-2-ID)Mucous Membrane Pemphigoid, Primary Sclerosing Cholangitis (PSC), Pemphigus vulgaris / foliaceus, Polymyositis/ DermatomyositisMedDRA version: 20.0Level: LLTClassification code: 10057069Term: Pemphigus foliaceus Class: 10040785MedDRA version: 20.1Level: LLTClassification code: 10036732Term: Primary sclerosing cholangitis Class: 10019805MedDRA version: 20.0Level: LLTClassification code: 10052802Term: Pemphigus vulgaris Class: 10040785MedDRA version: 20.0Level: PTClassification code: 10012503Term: Dermatomyositis Class: 100000004858MedDRA version: 20.0Level: PTClassification code: 10036102Term: Polymyositis Class: 100000004859MedDRA version: 25.0Level: PTClassification code: 10087064Term: Mucous membrane pemphigoid Class: 100000004858CTIS2023-510297-14-00niversitaetsklinikum Schleswig-Holstein AöR112
进行中（未招募）
1 期
Efficacy and safety of low-dose IL-2 (ld-IL-2) as a Treg enhancer for controlling neuro-inflammation in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patientsEUCTR2015-005347-14-GBCHU DE NIMES216
已完成
1 期
Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune SystemsHIV InfectionsNCT00006066National Institute of Allergy and Infectious Diseases (NIAID)92
已完成
1 期
A Study of Zidovudine Plus Interleukin-2 in HIV-Infected Patients Who Have No Symptoms of Infection But Who Have Tender Lymph NodesHIV InfectionsNCT00001005National Institute of Allergy and Infectious Diseases (NIAID)30